RVNC Revance Therapeutics Earnings per share growth this year

Corporate emblem and logo of Revance Therapeutics Inc (RVNC)

Revance Therapeutics (RVNC) develops biologics where sales growth effectively offsets high plant costs. On GURU.Markets, the year-over-year earnings per share trend clearly confirms this effect, with the indicator value standing at 0.00. A strict cold chain guarantees delivery quality, while a merger with a partner helped the brand survive aggressive pricing pressure in the aesthetics segment.

RVNC (Revance Therapeutics) Earnings growth in current year history from 07/04/2022 to 02/16/2025

Financial and market metric breakdowns for revance.com (RVNC)

- current quotes and average value forecast:
Basic company analysis:Revance Therapeutics, Inc
Finished products of Revance Therapeutics

Revance Therapeutics (RVNC) is completing its autonomous development phase in preparation for a subsequent merger with a major dermatological holding. The year-over-year earnings per share (EPS) trend measures the growth rate of net yield, stripping fundamental value from market noise. By analyzing the shift in EPS compared to last year, investors determine the business's financial stability prior to integrating the innovative drug portfolio into the overall corporate structure.